Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer

Table 1 Clinical features and follow-up of patients with ≤ GG3 and ≥ GG4 prostate cancer

	≤ GG3	≥ GG4	Pvalue
Patients, no.	9	9
Age, median (range)	68 (53–72.4)	65 (60–74)	0.8249^a
Gleason Grade Group, no. (%)
GG2	5 (56%)	0
GG3	4 (44%)	0
GG4	0	1 (11%)
GG5	0	8 (89%)
Clinical features, median (range)
PSA ng/mL	6.7 (4-11)	7 (4.3–22.6)	0.3072^a
Tumour volume	4 (0.7-7.1)	19.7 (0.7–30.2)	0.0103^a
Clinical features, no. (%)
Pathologic T stage 2	2 (22%)	2 (22%)	1.0^b
Pathologic T stage 3	7 (78%)	7 (78%)	1.0^b
Positive margins	6 (67%)	3 (33%)	0.6372^c
Extra-prostatic extension	7 (78%)	7 (78%)	1.0^c
Seminal vesicle invasion	3 (33%)	7 (78%)	0.1534^c
Lymph node metastases at diagnosis	0	4 (44%)	0.0824^c
Patient follow-up^d, no. (%)
Disease relapse^e	2 (25%)	8 (89%)	0.0030^e
Metastasis	1 (13%)	7 (78%)	0.0152^c
Castration-resistant prostate cancer	0 (0%)	3 (33%)	0.2059^c
Death from prostate cancer	0 (0%)	1 (11%)	1.0^c

^aUnpaired T test with Welch’s correction
^bThe Fisher exact test comparing the proportion of patients with T2 versus T3 disease
^cThe Fisher exact test comparing the proportion of patients with or without each clinical feature
^dFollow-up information was unavailable for one GG ≤ 3 patient, so n = 8
^eDisease relapse includes biochemical or clinical recurrence, HR = 6.937 (1.738–27.68), log rank test

ISSN: 1868-7083